Abivax (ADR)
Develops oral obefazimod for ulcerative colitis and Crohn's disease.
Something off on this page? Send us feedback.
Profile
Develops obefazimod, an investigational oral small molecule for inflammatory diseases, initially for moderately to severely active ulcerative colitis. The clinical-stage business is concentrated in obefazimod, with ulcerative colitis and Crohn's disease clinical programs.
Develops obefazimod, an investigational once-daily oral small molecule for inflammatory diseases. Its first intended use is moderately to severely active ulcerative colitis.
The program is built around enhancing miR-124 expression in immune cells. ABTECT is the Phase 3 ulcerative-colitis program, while ENHANCE-CD is a Phase 2b Crohn's-disease trial.
Founded in Paris, the clinical-stage company operates across France and the United States through a dual Euronext Paris and Nasdaq listing.
Its concentrated model depends on clinical-data interpretation, regulatory decisions, continued funding, and license rights from CNRS, the University of Montpellier, and Institut Curie.
Company facts
Key statistics
Year to date −15.3% · Average volume (30d) 873.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | Morgan Stanley | Reiterate | Overweight | $132 | $180 | |
| Jul 9, 2026 | Piper Sandler | Reiterate | Overweight | $142 | $175 | |
| Jul 2, 2026 | Truist Financial | Target | $135 | $155 | ||
| Jun 30, 2026 | Jefferies | Upgrade | Hold | Buy | $90 | $158 |
| Jun 30, 2026 | BTIG | Reiterate | Buy | $150 | $175 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | −$0.94 | −$0.71 | +23.9% | $401.1K | $1.5M | +277.3% | +3.62% |
| Mar 23, 2026Q4 FY25 | −$1.07 | −$1.22 | −14.2% | $1.8M | $512.2K | −71.6% | −4.55% |
| Sep 8, 2025Q2 FY25 | −$0.90 | −$0.86 | +4.4% | $1.4M | $2.4M | +70.6% | −0.83% |
| Mar 24, 2025Q4 FY24 | −$0.68 | −$1.55 | −128.0% | $3.1M | $7.7M | +146.2% | −0.41% |
Financial highlights
| 12 quarters | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $2.7M | $0 | $0 | $0 | $0 | |
| Gross profit | $2.6M | $2.7M | $0 | $0 | $0 | $0 | |
| Operating income | −$45.8M | −$107.1M | −$40.9M | −$54.7M | −$53.9M | −$231.2M | |
| Net income | −$60.2M | −$111.0M | −$44.9M | −$60.7M | −$56.1M | −$333.3M | |
| Diluted EPS | −$1.68 | −$2.29 | −$0.75 | −$1.74 | −$1.84 | −$2.43 | |
| Gross margin | 100.0% | 100.0% | — | — | — | — | |
| Operating margin | -1,758.7% | -3,975.2% | — | — | — | — |
Balance sheet, Dec 31, 2025Cash & short-term investments $614.3M · Total debt $53.2M · Total assets $755.5M · Shareholders' equity $527.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 73.43M · Float 67.11M · 91.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 6.01M | 8.18% | 13F | Aug 14, 2026 |
| Invus Public Equities, L.P. | 3.92M | 5.00% | 13G | Feb 13, 2026 |
| Darwin Global Management, Ltd. | 3.62M | 4.93% | 13F | Aug 14, 2026 |
| Helikon Investments Ltd | 2.79M | 3.80% | 13F | Aug 11, 2026 |
| Vestal Point Capital, LP | 2.35M | 3.20% | 13F | Aug 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- AbbVie
Oral advanced UC overlap through RINVOQ
- Pfizer
Oral UC overlap through VELSIPITY
- Bristol-Myers Squibb
Oral UC overlap through ZEPOSIA
- Eli Lilly
Advanced UC and Crohn's overlap through OMVOH
- Takeda (ADR)
Advanced UC and Crohn's overlap through ENTYVIO
- Johnson & Johnson
Advanced UC overlap through TREMFYA
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Abivax (ADR) | $113.67 | +0.31% | $8.32B | — | — | — | — |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 38.2 | 19.6 | 4.7 | +6.2% |